SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage
biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative
infections, today announced that on February 27, 2017, the Company's board of directors granted its recently appointed Chief
Commercial Officer, Janet Dorling, options to purchase an aggregate of 130,000 shares of the Company's common stock and 10,000
restricted stock units. Each stock option has an exercise price per share equal to $23.68, which was the closing trading price on
February 27, 2017, the effective date of the grant. The stock options and restricted stock units were granted pursuant to the
Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's board of directors in December 2014
under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the
Company.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and
commercialization of novel antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s
lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including
carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical
Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic
discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative
infections. All product candidates are investigational only and have not been approved for commercialization. For more information,
please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 hans@lifesciadvisors.com Media Contact: Denise Powell 510.703.9491 denise@redhousecomms.com
